Keywords: Sanofi, Multaq, CHMP, EMA, Restrictions, Atrial fibrillation

EMA recommends restricting use of Sanofi AF drug Multaq, but sees positive benefit-risk in some patients

Article | 23 September 2011

Print This

There was mixed news for French drug major Sanofi (Euronext: SAN) yesterday, when the European Medicines Agency's Committee for Medicinal ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in